Beacon Biosignals Extends Series B to $97M for AI-Driven Brain Data Platform
Beacon Biosignals just added another $11M to the stack, stretching its Series B to $97M and pushing total funding north of $132M. Not loud money. Smart money. The kind that listens before it speaks, then writes a check anyway. JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next stepped in like they’ve seen this movie before and already know how it ends.
Boston keeps producing these companies that don’t chase attention, they attract it. Beacon Biosignals is one of those. Clinical-grade EEG, AI doing the heavy lifting, and a platform that turns brain noise into signal that biopharma can actually use. That’s not a feature, that’s leverage. When your product helps drug development see clearer, faster, and with fewer blind spots, you’re not selling software, you’re selling time. And in clinical trials, time is the only currency that matters.
Jacob Donoghue and Jarrett Revels are building with that quiet confidence you only get when the tech holds up under pressure. No theatrics, just execution. The kind that gets General Catalyst, Innoviva, GV, S32, Catalio Capital Management, Logos Capital, Casdin Capital, Indicator Ventures and others to lean in early, then double down when the data starts talking back.
There’s a pattern here if you’re paying attention. Beacon Biosignals didn’t raise on vision alone. They earned it through positioning. Right market, right moment, right depth. Neurodiagnostics isn’t a side quest, it’s becoming core infrastructure for precision medicine. And Beacon didn’t show up with slides, they showed up with clinical-grade proof and a pipeline that biopharma actually needs.
The Dreem 3S device, the expanding neurodiagnostic dataset, the ability to run trials that don’t rely on guesswork dressed up as methodology. This is what happens when you respect the science and still move like a startup. Controlled chaos, but the kind that compounds.
The takeaway is simple, but not easy. If you want capital like this, build something that reduces uncertainty in a market drowning in it. Make your product unavoidable, not just impressive. Investors don’t fund potential forever. Eventually, they fund clarity. Beacon Biosignals is selling clarity to an industry that’s been operating in grayscale for too long. And now they’ve got $132M plus reasons to keep sharpening the picture.
